Iodixanol Nasal Solution Reduces Allergic Rhinoconjunctivitis Signs and Symptoms in Allergen BioCube®: Randomized Clinical Trial

Importance: Allergic rhinitis affects about 20% of the population worldwide. Available pharmacological treatments are helpful but not ideal in providing relief; safer and more effective treatments are needed. Objective: To evaluate the efficacy and safety of Nasapaque nasal solution vs placebo for relief or prophylactic treatment of seasonal allergic rhinitis. Design: Single-center, double-masked, RCT (March to July 2015) conducted outside of ragweed season. Setting: Study conducted in the Allergen BioCube®. Participants: Adult subjects (aged ≥ 18 years) with history of allergic rhinitis, positive skin test for ragweed, and positive BioCube challenge response.